Company news

AdAlta Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Extension of Victorian Government RDTI Loan Facility

April 28, 2024

Institutional investment to pursue strategic initiatives

April 28, 2024

SYNBV MoU Webinar presentation

April 9, 2024

SYNThesis BioVentures MoU for cellular immunotherapies

April 7, 2024

Corporate Presentation

March 7, 2024

Positive AD-214 Phase I extension study results

March 5, 2024

January 2024 partnering presentations and progress

January 21, 2024

New malaria inhibiting i-body

December 18, 2023

Chair address and CEO presentation to AGM

November 21, 2023

AD-214 Phase I extension clinical study - interim results

November 20, 2023

AdAlta closes oversubscribed $1.65 million raise

November 8, 2023

Oversubscribed placement result

November 6, 2023

Placement to raise up to $1.23million

November 2, 2023

AD-214 well tolerated in Phase I extension study

October 22, 2023

R&D tax refund received & R&D Loan repayment terms extended

October 17, 2023

Prof Foley invited presentation AD-214

September 25, 2023

Dosing simulations support AD-214 IV product profile

September 24, 2023

AD-214 Phase I extension study fully enrolled

September 19, 2023

AdAlta to Present at August 24th Virtual Investor Summit

August 16, 2023

AD-214 returns to clinic

August 3, 2023

$1.87 million raised in oversubscribed Shortfall facility

July 12, 2023

New AD-214 data de-risks clinical studies

July 6, 2023

AD-214 clinical trial approval

June 28, 2023

AdAlta to present at June 1 Virtual Investor Summit

May 30, 2023

AdAlta secures A$1.28 million in rights offer to advance AD-214

May 25, 2023

Rights Offer results

May 24, 2023

AdAlta to support early return to clinical trials of AD-214 with rights offer

May 1, 2023

Rights Offer to fund early return to clinic and growth

April 27, 2023

Publication highlights I-body potential in osteoporosis

January 24, 2023

AdAlta welcomes new substantial shareholders

January 23, 2023

Second Japan patent for AD-214

January 9, 2023

AD-214 progress and priorities webinar presentation

November 1, 2022

AD-214 progress and priorities

November 1, 2022

Balance of R&D Tax Incentive Refund received

October 26, 2022

1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer

October 12, 2022

R&D Tax Incentive Refund received

October 3, 2022

Quarterly Appendix 4C and Activities Report

July 24, 2022

AD-214 program update, cash runway extension

July 3, 2022

European Patent for AD-214 granted

June 13, 2022

BIO International Convention presentation

May 31, 2022

AdAlta presentation at Bioshares Biotech Summit

May 9, 2022

Indian patent for AD-214

April 6, 2022

Inhaled AD-214 preclinical program

April 4, 2022

PAC Partners Healthcare Conference - Corporate Presentation

April 4, 2022

$1.6M Second Tranche R&D Cash Flow Loan Received

March 8, 2022

Chinese patent granted for AD-214

March 1, 2022

Change in Director Interest Notice x 4

February 10, 2022

Application for quotation of securities - 1AD

February 6, 2022

Entitlement Offer Results

February 3, 2022

Presentation to Share Cafe Webinar

January 19, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 84 decks. Every deck is listed under its year.